Cargando…

Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling

AIMS: In patients at high risk of heart failure following myocardial infarction (MI) as a result of residual left ventricular systolic dysfunction (LVSD), the angiotensin receptor neprilysin inhibitor sacubitril/valsartan may result in a greater attenuation of adverse left ventricular (LV) remodelli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Docherty, Kieran F., Campbell, Ross T., Brooksbank, Katriona J.M., Godeseth, Rosemary L., Forsyth, Paul, McConnachie, Alex, Roditi, Giles, Stanley, Bethany, Welsh, Paul, Jhund, Pardeep S., Petrie, Mark C., McMurray, John J.V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7835504/ https://www.ncbi.nlm.nih.gov/pubmed/33305513 http://dx.doi.org/10.1002/ehf2.13137

Ejemplares similares

Effect of Neprilysin Inhibition on Left Ventricular Remodeling in Patients With Asymptomatic Left Ventricular Systolic Dysfunction Late After Myocardial Infarction
por: Docherty, Kieran F., et al.
Publicado: (2021)

Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)
por: Lee, Matthew M.Y., et al.
Publicado: (2020)

The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan
por: Jhund, Pardeep S, et al.
Publicado: (2016)

Adverse Outcomes Associated With Interleukin-6 in Patients Recently Hospitalized for Heart Failure With Preserved Ejection Fraction
por: Mooney, Leanne, et al.
Publicado: (2023)

Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics
por: Yeoh, Su Ern, et al.
Publicado: (2023)

Cost‐effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health‐economic analysis of DAPA‐HF
por: McEwan, Phil, et al.
Publicado: (2020)

Rationale and Design of the Genotype-Blinded Trial of Torasemide for the Treatment of Hypertension (BHF UMOD)
por: McCallum, Linsay, et al.
Publicado: (2020)

The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context
por: McMurray, John J V, et al.
Publicado: (2020)

Rationale and design of the British Heart Foundation (BHF) Coronary Microvascular Angina (CorMicA) stratified medicine clinical trial()()
por: Ford, Thomas J., et al.
Publicado: (2018)

Within trial comparison of survival time projections from short‐term follow‐up with long‐term follow‐up findings
por: Ferreira, João Pedro, et al.
Publicado: (2022)

Drug therapy for heart failure with reduced ejection fraction: what is the ‘right’ dose?
por: Kondo, Toru, et al.
Publicado: (2022)

Vitamin K for kidney transplant organ recipients: investigating vessel stiffness (ViKTORIES): study rationale and protocol of a randomised controlled trial
por: Lees, Jennifer Susan, et al.
Publicado: (2020)

Estimating the Lifetime Benefits of Treatments for Heart Failure
por: Ferreira, João Pedro, et al.
Publicado: (2020)

Efficacy of implantable haemodynamic monitoring in heart failure across ranges of ejection fraction: a systematic review and meta-analysis
por: Curtain, James P, et al.
Publicado: (2023)

Eligibility for pharmacological therapies in heart failure with reduced ejection fraction: implications of the new Chronic Kidney Disease Epidemiology Collaboration creatinine equation for estimating glomerular filtration rate
por: Butt, Jawad H., et al.
Publicado: (2022)

Which patients with heart failure should receive specialist palliative care?
por: Campbell, Ross T., et al.
Publicado: (2018)

SOLOIST‐WHF and updated meta‐analysis: sodium–glucose co‐transporter 2 inhibitors should be initiated in patients hospitalized with worsening heart failure
por: Docherty, Kieran F., et al.
Publicado: (2020)

Rationale and design of the Coronary Microvascular Angina Cardiac Magnetic Resonance Imaging (CorCMR) diagnostic study: the CorMicA CMR sub-study
por: Corcoran, David, et al.
Publicado: (2018)

Association is not causation: treatment effects cannot be estimated from observational data in heart failure
por: Rush, Christopher J, et al.
Publicado: (2018)

Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction
por: Dewan, Pooja, et al.
Publicado: (2019)

The novel urinary proteomic classifier HF1 has similar diagnostic and prognostic utility to BNP in heart failure
por: Campbell, Ross T., et al.
Publicado: (2020)

Treatment of Type 2 Diabetes and Outcomes in Patients With Heart Failure: A Nested Case–Control Study From the U.K. General Practice Research Database
por: MacDonald, Michael R., et al.
Publicado: (2010)

Rationale and design of the British Heart Foundation (BHF) Coronary Microvascular Function and CT Coronary Angiogram (CorCTCA) study
por: Sidik, Novalia P, et al.
Publicado: (2020)

Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction
por: Serenelli, Matteo, et al.
Publicado: (2020)

Effect of sacubitril/valsartan on investigator‐reported ventricular arrhythmias in PARADIGM‐HF
por: Curtain, James P., et al.
Publicado: (2022)

Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction
por: Rørth, Rasmus, et al.
Publicado: (2019)

Total Reactive Isocyanate Group (TRIG) Measurement: A Commentary
por: McConnachie, Glen, et al.
Publicado: (2023)

Initiation of domiciliary care and nursing home admission following first hospitalization of heart failure patients: a nationwide cohort study
por: Rørth, Rasmus, et al.
Publicado: (2018)

Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA‐HF
por: McDowell, Kirsty, et al.
Publicado: (2022)

What can we learn from RELAX-AHF compared to previous AHF trials and what does the future hold?
por: Cannon, Jane A, et al.
Publicado: (2015)

Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF
por: Yeoh, Su Ern, et al.
Publicado: (2023)

Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF
por: Curtain, James P, et al.
Publicado: (2021)

The Rationale for Angiotensin Receptor Neprilysin Inhibitors in a Multi-Targeted Therapeutic Approach to COVID-19
por: Bellis, Alessandro, et al.
Publicado: (2020)

Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial
por: Wachter, Rolf, et al.
Publicado: (2020)

Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF
por: Docherty, Kieran F., et al.
Publicado: (2022)

Insights into foundational therapies for heart failure with reduced ejection fraction
por: McMurray, John J. V., et al.
Publicado: (2022)

Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF
por: Jhund, Pardeep S., et al.
Publicado: (2021)

Palliative care needs in patients hospitalized with heart failure (PCHF) study: rationale and design
por: Campbell, Ross T., et al.
Publicado: (2015)

Antidepressant treatment and cultural differences - a survey of the attitudes of physicians and patients in Sweden and Turkey
por: Wade, Alan G, et al.
Publicado: (2010)

Temporal trends in hospitalisation for stroke recurrence following incident hospitalisation for stroke in Scotland
por: Lewsey, James, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_9bds00fmss833t4uvulkipo0bh